全文获取类型
收费全文 | 424004篇 |
免费 | 49132篇 |
国内免费 | 3711篇 |
专业分类
耳鼻咽喉 | 7855篇 |
儿科学 | 12594篇 |
妇产科学 | 7437篇 |
基础医学 | 40359篇 |
口腔科学 | 6476篇 |
临床医学 | 53379篇 |
内科学 | 103862篇 |
皮肤病学 | 11293篇 |
神经病学 | 40334篇 |
特种医学 | 15551篇 |
外国民族医学 | 27篇 |
外科学 | 80410篇 |
综合类 | 4950篇 |
现状与发展 | 73篇 |
一般理论 | 320篇 |
预防医学 | 30388篇 |
眼科学 | 10373篇 |
药学 | 20212篇 |
12篇 | |
中国医学 | 990篇 |
肿瘤学 | 29952篇 |
出版年
2024年 | 835篇 |
2023年 | 6027篇 |
2022年 | 4073篇 |
2021年 | 9196篇 |
2020年 | 9417篇 |
2019年 | 8012篇 |
2018年 | 13771篇 |
2017年 | 11957篇 |
2016年 | 13363篇 |
2015年 | 14447篇 |
2014年 | 24084篇 |
2013年 | 27718篇 |
2012年 | 25032篇 |
2011年 | 25925篇 |
2010年 | 21521篇 |
2009年 | 23695篇 |
2008年 | 23440篇 |
2007年 | 22663篇 |
2006年 | 24800篇 |
2005年 | 22055篇 |
2004年 | 20188篇 |
2003年 | 18015篇 |
2002年 | 17074篇 |
2001年 | 6742篇 |
2000年 | 5466篇 |
1999年 | 6196篇 |
1998年 | 6779篇 |
1997年 | 6042篇 |
1996年 | 5546篇 |
1995年 | 5261篇 |
1994年 | 3766篇 |
1993年 | 3217篇 |
1992年 | 3062篇 |
1991年 | 2957篇 |
1990年 | 2442篇 |
1989年 | 2498篇 |
1988年 | 2368篇 |
1987年 | 2113篇 |
1986年 | 2148篇 |
1985年 | 1994篇 |
1984年 | 1972篇 |
1983年 | 1783篇 |
1982年 | 1967篇 |
1981年 | 1787篇 |
1980年 | 1572篇 |
1979年 | 1200篇 |
1978年 | 1156篇 |
1977年 | 1134篇 |
1976年 | 925篇 |
1975年 | 832篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
42.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
43.
44.
45.
46.
47.
48.
Victor Aboyans Louis Labrousse Philippe Lacroix Jér?me Guilloux Seifeddine Sekkal Alexandre Le Guyader Elisabeth Cornu Marc Laskar 《European journal of cardio-thoracic surgery》2006,30(2):300-304
BACKGROUND: Despite major improvement in surgical techniques and intensive care management, stroke remains one of the most devastating complications of coronary artery bypass grafting (CABG). We aimed to determine factors predicting the occurrence of stroke during CABG. A special interest was focused on preoperative therapies. METHODS: We prospectively enrolled 810 consecutive candidates for CABG alone in a specific database, including all pre- and perioperative data (history, clinical, therapeutic, cardiac catheterization, surgical and intensive care data). Univariate tests and then multiple logistic regression analysis were used to determine independent predictive factors. RESULTS: During the first postoperative month, stroke occurred in 11 cases and transient ischemic attack (TIA) in 4 additive cases (cumulative rate: 1.85%). After the multivariate analysis, the following factors remained significant (p<0.05) in the predictive model, with corresponding odds ratios between brackets: redo cardiac surgery (7.45), unstable cardiac status (4.74), past history of cerebrovascular disease (4.14), past history of peripheral arterial disease (3.55), whereas the presence of preoperative statins was protective (0.24, 95% IC: 0.07-0.78). The addition of perioperative data (aortic calcification, postoperative arrhythmia, on/off-pump surgery) did not change the final predictive model. CONCLUSION: To our knowledge, this is the first real-world observational report highlighting the interest of statins for the prevention of stroke in the very special situation of CABG. Even though according to randomized trials coronary patients have a benefit from these drugs, a special level of interest should be directed towards those presenting the above-mentioned risk factors. 相似文献
49.
50.
Lucia Nogovà MD Volker Diehl MD Andreas Engert MD 《Current hematologic malignancy reports》2006,1(1):60-65
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) differs in histologic and clinical presentation from classical Hodgkin’s
lymphoma (cHL). Treatment of LPHL patients using standard Hodgkin’s lymphoma protocols leads to complete remission in more
than 95% of patients. Survival and freedom from treatment failure are substantially worse in advanced-stage patients than
for early-stage patients. Thus, patients in advanced stages and those in early stages with unfavorable risk factors should
be treated similar to those with cHL. In contrast, patients with early-stage LPHL without risk factors might be sufficiently
treated with reduced-intensity programs having less severe adverse effects. As a result, treatment of early LPHL is rather
heterogeneous, including radiotherapy using extended-fleld technique, involved-fleld radiotherapy (IF-RT), combined-modality
treatment, and, more recently, monoclonal antibodies. Watch-and-wait strategy plays an important role in pediatric oncology,
to avoid adverse effects associated with therapy. IF-RT seems to be emerging as a treatment of choice for patients with stage
IA LPHL; most larger study groups, such as the German Hodgkin Study Group and the European Organisation for Research and Treatment
of Cancer, have adopted IF-RT as the treatment of choice for these patients. 相似文献